Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

Calvin J. Cohen, Jean Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank Rhame, Hans Jürgen Stellbrink, Taisheng Li, Herta Crauwels, Laurence Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load

Original languageEnglish
Pages (from-to)939-950
Number of pages12
JournalAIDS (London, England)
Volume27
Issue number6
DOIs
Publication statusPublished - Mar 27 2013

Fingerprint

Rilpivirine
efavirenz
HIV-1
Safety
Reverse Transcriptase Inhibitors
Viral Load
Nucleosides
Nucleotides
Therapeutics

Keywords

  • Efavirenz
  • HIV-1
  • Rilpivirine
  • Treatment naive

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Cohen, C. J., Molina, J. M., Cassetti, I., Chetchotisakd, P., Lazzarin, A., Orkin, C., ... Boven, K. (2013). Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (London, England), 27(6), 939-950. https://doi.org/10.1097/QAD.0b013e32835cee6e

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. / Cohen, Calvin J.; Molina, Jean Michel; Cassetti, Isabel; Chetchotisakd, Ploenchan; Lazzarin, Adriano; Orkin, Chloe; Rhame, Frank; Stellbrink, Hans Jürgen; Li, Taisheng; Crauwels, Herta; Rimsky, Laurence; Vanveggel, Simon; Williams, Peter; Boven, Katia.

In: AIDS (London, England), Vol. 27, No. 6, 27.03.2013, p. 939-950.

Research output: Contribution to journalArticle

Cohen, CJ, Molina, JM, Cassetti, I, Chetchotisakd, P, Lazzarin, A, Orkin, C, Rhame, F, Stellbrink, HJ, Li, T, Crauwels, H, Rimsky, L, Vanveggel, S, Williams, P & Boven, K 2013, 'Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials', AIDS (London, England), vol. 27, no. 6, pp. 939-950. https://doi.org/10.1097/QAD.0b013e32835cee6e
Cohen, Calvin J. ; Molina, Jean Michel ; Cassetti, Isabel ; Chetchotisakd, Ploenchan ; Lazzarin, Adriano ; Orkin, Chloe ; Rhame, Frank ; Stellbrink, Hans Jürgen ; Li, Taisheng ; Crauwels, Herta ; Rimsky, Laurence ; Vanveggel, Simon ; Williams, Peter ; Boven, Katia. / Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. In: AIDS (London, England). 2013 ; Vol. 27, No. 6. pp. 939-950.
@article{71d00d3c94b34d3a89eb4fb239611d76,
title = "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials",
abstract = "Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate ({\%} confirmed viral load",
keywords = "Efavirenz, HIV-1, Rilpivirine, Treatment naive",
author = "Cohen, {Calvin J.} and Molina, {Jean Michel} and Isabel Cassetti and Ploenchan Chetchotisakd and Adriano Lazzarin and Chloe Orkin and Frank Rhame and Stellbrink, {Hans J{\"u}rgen} and Taisheng Li and Herta Crauwels and Laurence Rimsky and Simon Vanveggel and Peter Williams and Katia Boven",
year = "2013",
month = "3",
day = "27",
doi = "10.1097/QAD.0b013e32835cee6e",
language = "English",
volume = "27",
pages = "939--950",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

AU - Cohen, Calvin J.

AU - Molina, Jean Michel

AU - Cassetti, Isabel

AU - Chetchotisakd, Ploenchan

AU - Lazzarin, Adriano

AU - Orkin, Chloe

AU - Rhame, Frank

AU - Stellbrink, Hans Jürgen

AU - Li, Taisheng

AU - Crauwels, Herta

AU - Rimsky, Laurence

AU - Vanveggel, Simon

AU - Williams, Peter

AU - Boven, Katia

PY - 2013/3/27

Y1 - 2013/3/27

N2 - Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load

AB - Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load

KW - Efavirenz

KW - HIV-1

KW - Rilpivirine

KW - Treatment naive

UR - http://www.scopus.com/inward/record.url?scp=84876406278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876406278&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835cee6e

DO - 10.1097/QAD.0b013e32835cee6e

M3 - Article

VL - 27

SP - 939

EP - 950

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 6

ER -